Extrawell Pharmaceutical Holdings Limited (0858) AI Stock Analysis

• Market Cap: HK$329.82M
• Dividend Yield: N/A
• Average Volume (3M): 32.61M
• Price to Earnings (P/E): 1.5
• Beta (1Y): 0.76
• Revenue Growth: -12.93%
• EPS Growth: N/A
• Country: HK
• Employees: 162
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.05
• Shares Outstanding: 2,390,000,200
• 10 Day Avg. Volume: 37,875,000
• 30 Day Avg. Volume: 32,611,666
• PEG Ratio: <0.01
• Price to Book (P/B): 0.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 124.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: ―

Extrawell Pharmaceutical Holdings Limited struggles with declining revenue, negative profitability, and poor cash flow management. Despite a strong equity position, these issues pose risks to its financial health. Technical indicators suggest a bearish market sentiment, while the low P/E ratio implies potential undervaluation. The lack of earnings call data and corporate events further limits insights into future prospects.

Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company Description

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.

How the Company Makes Money

Extrawell Pharmaceutical Holdings Limited generates revenue primarily through the sale of its pharmaceutical products. The company manufactures and markets a range of prescription and over-the-counter drugs, which are distributed across various regions. Key revenue streams include domestic and international sales of their products. An essential factor contributing to the company's earnings is its continuous investment in research and development to innovate and enhance its product line, enabling it to meet market demands and maintain competitive advantage. Additionally, strategic partnerships and collaborations with other pharmaceutical entities can play a significant role in expanding its market reach and enhancing revenue growth.

Extrawell Pharmaceutical Holdings Limited Financial Statement Overview

Summary

Extrawell Pharmaceutical Holdings Limited faces challenges in profitability and cash flow management. Despite a strong equity position, the company needs to address its operational inefficiencies and improve revenue generation to ensure long-term financial health. Continued negative earnings and cash flow trends could impact future growth and stability.

Income Statement

Extrawell Pharmaceutical Holdings Limited has shown declining revenue over the past couple of years, with a significant drop from HKD 72.58 million in 2023 to HKD 59.10 million in 2024. The net income has turned negative in 2024, indicating profitability issues. Gross profit margin has decreased, and EBIT and EBITDA margins are negative, suggesting operational challenges.

Balance Sheet

The company maintains a strong equity position with an equity ratio of approximately 86% in 2024, indicating financial stability. However, the debt-to-equity ratio has improved due to reduced liabilities, but still requires monitoring. Return on equity is negative due to net losses, showing a need for improved profitability.

Cash Flow

Extrawell's cash flow situation is concerning, with negative operating cash flow and free cash flow in 2024. The free cash flow has declined from 2023, indicating a potential liquidity issue. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	59.10M	72.58M	73.92M	78.80M	77.58M
Gross Profit	28.78M	31.14M	37.56M	42.57M	42.92M
EBITDA	-129.52M	159.05M	157.84M	-97.48M	101.14M
Net Income	-162.95M	129.26M	130.59M	-121.10M	83.28M
Balance Sheet
Total Assets	1.29B	1.44B	1.32B	1.16B	1.27B
Cash, Cash Equivalents and Short-Term Investments	95.01M	123.96M	135.52M	150.18M	149.58M
Total Debt	120.41M	615.58M	597.67M	586.23M	576.89M
Total Liabilities	174.58M	671.28M	659.53M	642.36M	633.53M
Stockholders Equity	1.11B	769.36M	653.29M	518.15M	630.14M
Cash Flow
Free Cash Flow	-4.89M	-3.40M	-11.23M	-953.00K	-10.42M
Operating Cash Flow	-3.69M	3.21M	-1.60M	-232.00K	-10.26M
Investing Cash Flow	2.04M	-12.50M	-9.63M	-681.00K	-9.83M
Financing Cash Flow	-6.50M	-2.29M	-1.80M	-1.69M	-208.00K

Extrawell Pharmaceutical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0858, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.08, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 78.61 is Negative, neither overbought nor oversold. The STOCH value of 81.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0858.

Extrawell Pharmaceutical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
0858	50 Neutral	HK$329.82M	1.48	23.02%	―	-12.93%	―
0911	49 Neutral	HK$41.51M	31.82	0.34%	―	-45.94%	―
8622	48 Neutral	HK$185.17M	―	-7.93%	―	1.13%	38.41%
1498	48 Neutral	HK$189.57M	―	-26.80%	―	-6.09%	66.59%
1652	43 Neutral	HK$264.68M	―	-40.39%	―	-43.73%	-434.56%
1312	36 Underperform	HK$184.10M	―	-7.42%	―	10.93%	-159.62%

Extrawell Pharmaceutical Holdings Limited Corporate Events

Extrawell Pharmaceutical Approves New Auditor Appointment at SGM

Extrawell Pharmaceutical Holdings Limited announced that the resolution to appoint SFAI (HK) CPA Limited as the company’s auditor was approved by shareholders at the special general meeting held on March 28, 2025. The resolution passed with overwhelming support, reflecting shareholder confidence in the company’s governance and operational oversight. This decision is expected to strengthen the company’s financial auditing processes, potentially enhancing its industry positioning and stakeholder trust.

Extrawell Pharmaceutical Adjusts Shareholder Meeting Procedures

Extrawell Pharmaceutical Holdings Limited has announced a change regarding the proposed appointment of an auditor and the special general meeting. The company has decided to cancel the previously announced book closure period, allowing shareholders to transfer shares until 27 March 2025 to be eligible to attend and vote at the meeting. This decision reflects the company’s commitment to ensuring shareholder participation and transparency in its governance processes.

Extrawell Pharmaceutical Announces Special General Meeting for Auditor Appointment

Extrawell Pharmaceutical Holdings Limited has announced a special general meeting to be held on March 28, 2025, in Hong Kong. The primary agenda is to appoint SFAI (HK) CPA Limited as the company’s auditor until the next annual general meeting, with the board authorized to set the auditor’s remuneration. This decision could impact the company’s financial transparency and stakeholder confidence.